Drug Database
Back to search

Poland· PL-100481280

Levobupivacaine Molteni

A levobupivacaine product containing levobupivacainum, registered in Poland by L.Molteni & C. dei F.lli Alitti Societa di Esercizio S.p.A.. The same ATC class is registered in 10 of our 19 countries.

ATC N01BB10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLevobupivacaine MolteniATCN01BB10REGISTER NO.PL-100481280PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about levobupivacainumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Levobupivacaine is registered in 10 of 19 countries.

Countries holding a registration under ATC N01BB10 (levobupivacaine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search levobupivacaine products by name

Levobupivacaine · ATC N01BB10

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Levobupivacainum
Manufacturer
L.Molteni & C. dei F.lli Alitti Societa di Esercizio S.p.A.
Country
Poland (PL)
ATC code
N01BB10
ATC class
Levobupivacaine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991523206

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

101 interactions on record for levobupivacaine.

Graded by severity as the source publishes them — 73 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check levobupivacaine against other medicinesHow interaction checks work

Levobupivacaine · interactions on record

101 records

  • 73 moderate
  • 28 minor

Most severe, free to view

  • ClotrimazoleA01AB18moderate
  • LidocainA01AE01moderate
  • CimetidineA02BA01moderate
  • AprepitantA04AD12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Levobupivacaine in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All levobupivacaine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Belgium · Levobupivacaine Fresenius Kabi
  • Czechia · Levobupivacaine Kabi
  • Spain · Levobupivacaína Altan, Levobupivacaína Kabi
  • France · Levobupivacaine Altan, Levobupivacaine Kabi
  • United Kingdom (Northern Ireland) · Levobupivacaine, Levobupivacaine Altan
  • Croatia · Levobupivakain Kabi
  • Ireland · Levobupivacaine
  • Italy · Levobupivacaina Altan, Levobupivacaina Bioindustria L.I.M
  • Netherlands · Levobupivacaïne Fresenius Kabi, Levobupivacaïne Molteni
  • Portugal · Levobupivacaína Altan, Levobupivacaína Kabi
  • Sweden · Levobupivacaine Molteni
  • Slovenia · Levobupivakain Kabi
  • Slovakia · Levobupivacaine Kabi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/44a234f8-700d-4d06-bbb2-bf97de819d7a
GET /v1/drugs/44a234f8-700d-4d06-bbb2-bf97de819d7a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań / do infuzji",
  "source": "urpl",
  "strength": "2,5 mg/ml",
  "packaging": "05909991523206 ¦ Lz ¦ 151602\n10 amp. 10 ml",
  "substance": "Levobupivacainum 2.5 mg/ml",
  "common_name": "Levobupivacainum",
  "pl_product_id": "100481280",
  "pozwolenie_nr": "28050",
  "auth_procedure": "MRP",
  "authorisation_validity": "2028-10-10"
}
API referenceMCP serverPlans

See everything about levobupivacaine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console